(Reuters) - CV Therapeutics, whose key product is chronic angina drug
Ranexa, did not elaborate further on the range of options it
will consider. Angina typically refers to chest pain caused by
reduced flow of blood to the heart muscle.
In May, Palo Alto, California-based CV Therapeutics
announced a plan to cut jobs and reduce the number of sales
territories to lower operating expenses, and said it was
looking for a partner.
Read more at Reuters.com Mergers News
Ranexa, did not elaborate further on the range of options it
will consider. Angina typically refers to chest pain caused by
reduced flow of blood to the heart muscle.
In May, Palo Alto, California-based CV Therapeutics
announced a plan to cut jobs and reduce the number of sales
territories to lower operating expenses, and said it was
looking for a partner.
Read more at Reuters.com Mergers News
No comments:
Post a Comment